Oncolytic Viruses: Monotherapies vs. Combination Therapy

Deep Dive into Combinations with PD-1/PD-L1 Inhibitors and CAR-T Therapies

In recent years, the field of cancer therapeutics has witnessed a growing interest in the study of oncolytic viruses (OVs) as part of combination therapy regimens . Although current approvals for OV treatments are primarily for monotherapy, emerging evidence suggests that they exhibit enhanced efficacy when utilized in conjunction with other therapies. The combination of OVs with other treatments, including PD-1/PD-L1 inhibitors and CAR-T cell therapies , holds great promise in improving cancer treatment outcomes.

Access Beacon’s latest report to explore the rationale behind combining OVs with different treatment modalities, as opposed to using monotherapies, and view the positive results observed in current trials.

Oncolytic Viruses

This report offers a comprehensive analysis of the following key areas:

Current landscape: Gain a thorough understanding of the existing landscape for both monotherapy and combination therapies in the field of oncolytic viruses
Most common therapeutic classes: Discover the most prevalent therapeutic classes that are being utilized in conjunction with OV treatments, shedding light on the emerging trends and synergies
Effects of PD-1/PD-L1 and CAR-T combination therapies: Explore the outcomes and implications in combining the two prominent approaches in the field of immuno-oncology with OVs

Full Download Here

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs